Workshop on the role of registries in the monitoring of cancer therapies based on genetic and molecular features
Date:
29/11/2019
Location:
European Medicines Agency, Amsterdam, the Netherlands
The aim of the workshop is to investigate the feasibility of using disease registries for cancer therapies based on genetic and molecular features.
The objectives are to agree on:
- core data elements that should be collected in cancer registries to support regulatory assessment of long term safety and effectiveness of new cancer treatments;
- quality assurance measures necessary to ensure registry data are of suitable quality to support regulatory evaluation and to permit registries interoperability;
- practical considerations for accessing and sharing data to be used for regulatory purposes.
-
List item
Agenda - Workshop on the role of registries in the monitoring of cancer therapies based on genetic and molecular features (PDF/85.01 KB)
First published: 04/10/2019
Last updated: 04/11/2019
EMA/499786/2019 -
List item
Presentation - Workshop on the role of registries in the monitoring of cancer therapies based on genetic and molecular features: Introduction from the chair (Peter Mol) (PDF/1.32 MB)
First published: 05/12/2019 -
List item
Presentation - A regulatory view on the role of registries for generating data on cancer therapies (Filip Josephson) (PDF/913.72 KB)
First published: 05/12/2019 -
List item
Presentation - The European Network of Cancer Registries (ENCR) (Otto Visser) (PDF/1.06 MB)
First published: 05/12/2019 -
List item
Presentation - Registries for European Reference Networks (ERNs) (Hélène Le Borgne) (PDF/920.97 KB)
First published: 05/12/2019 -
List item
Presentation - The National Cancer Registration and Analysis Service (NCRAS) England: Data collection for tumour agnostic treatments (Alice Turnbull) (PDF/5.81 MB)
First published: 05/12/2019